Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Employees: 11-50
Total raised: $10M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Paul Gross... | paulgrossi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.09.2017 | Seed | $10M | - |
Mentions in press and media 4
| Date | Title | Description |
| 16.03.2020 | Ben Franklin Companies Fighting Infectious Disease and its Effects | While southeastern Pennsylvania has numerous large companies working on novel technologies to address these issues across many aspects of pandemic mitigation – vaccines, therapeutics, diagnostics, surveillance/epidemiology, devices, manufac... |
| 07.09.2017 | Term Sheet — Thursday, September 7 | SPORTS TALK Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop The company also announced a strategic investment and partnership with the NFL Players Association through the OneTeam... |
| 06.09.2017 | Excision BioTherapeutics Completes $10M Seed Financing | Excision BioTherapeutics, a Philadelphia, PA-based life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, comp... |
| 06.09.2017 | Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures | Excision BioTherapeutics, a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, today announced it has comp... |